755 related articles for article (PubMed ID: 32311895)
21. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
22. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
[TBL] [Abstract][Full Text] [Related]
23. Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
Hu GH; Zhao XY; Zuo YX; Chang YJ; Suo P; Wu J; Jia YP; Lu AD; Li YC; Wang Y; Jiao SC; Zhang LJ; Kong J; Yan CH; Xu LP; Zhang XH; Liu KY; Cheng YF; Wang Y; Zhang LP; Huang XJ
Leukemia; 2021 Nov; 35(11):3092-3100. PubMed ID: 33824464
[TBL] [Abstract][Full Text] [Related]
24. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy.
Li Z; An N; Yang K; Meng F; Xu T; Peng X; Wen X; Li J; Song Y; Yang R; Wu T
Transplant Cell Ther; 2023 Mar; 29(3):167-173. PubMed ID: 36427783
[TBL] [Abstract][Full Text] [Related]
25. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation.
Song Y; Liu Z; Wang Q; Gao K; Wu T
Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
[TBL] [Abstract][Full Text] [Related]
27. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H
Front Immunol; 2024; 15():1389227. PubMed ID: 38803489
[TBL] [Abstract][Full Text] [Related]
28. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
[TBL] [Abstract][Full Text] [Related]
30. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
31. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
32. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and safety of TBI+rATG-based conditioning regimen for haploidentical allogeneic hematopoietic stem cell transplantation in 11 cases of chemotherapy-resistant advanced peripheral T-cell lymphoma].
Xu R; Li S; Liu HX; Wei DL; Jiang Y; Wang JJ; Liu SS; Wang C; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):578-581. PubMed ID: 37749039
[No Abstract] [Full Text] [Related]
34. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
35. [Targeted immunotherapy efficacy analysis in patients with relapsed/refractory B cell acute lymphocytic leukemia].
Su Y; Bao S; Wei YP; Song LJ; Xue YM; Wei XD; Song YP; Yin QS
Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):946-951. PubMed ID: 36709187
[No Abstract] [Full Text] [Related]
36. Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation.
Li Y; Li Y; Zhang M; Zhao H; Zhu M; Huang H; Hu Y
Eur J Haematol; 2024 Jan; 112(1):94-101. PubMed ID: 37477866
[TBL] [Abstract][Full Text] [Related]
37. Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph
Han L; Zhao R; Yang J; Zu Y; Liu Y; Zhou J; Li L; Huang Z; Zhang J; Gao Q; Song Y; Zhou K
Front Immunol; 2022; 13():965932. PubMed ID: 36225940
[TBL] [Abstract][Full Text] [Related]
38. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
[TBL] [Abstract][Full Text] [Related]
39. Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial.
Luo Y; Gao L; Liu J; Yang L; Wang L; Lai X; Gao S; Liu L; Zhao L; Ye Y; Wang M; Shen L; Cao WW; Wang D; Li W; Zhang X; Huang H
EClinicalMedicine; 2024 Jan; 67():102377. PubMed ID: 38204488
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]